MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

erythrocytosis

  • Home
  • erythrocytosis
Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents
Posted inDiabetes & Endocrinology news Oncology

Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents

Posted by By MedXY 06/28/2026
Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control rate.
Read More
Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors
Posted inCardiology Specialties

Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors

Posted by By MedXY 08/11/2025
This article explores the incidence of erythrocytosis and thromboembolic risk in heart failure patients treated with SGLT2 inhibitors, revealing a higher incidence of erythrocytosis but no associated increase in thromboembolic events over one year.
Read More
  • Awake Integrated Microsurgical Approach for Head and Neck Free Flap Reconstruction in Frail Patients: A Safe and Resource-Efficient Alternative to General Anesthesia
  • Hospital Variation in Early Tracheostomy and Life-Sustaining Treatment Withdrawal in Severe TBI: Insights from a Nationwide Study
  • Exploring ICU Staff Perspectives on Brain Death: Insights from a Swiss Multicenter Survey
  • International Validation of Sepsis Temperature-Trajectory Subphenotypes Reveals Immune and Coagulation Profiles with Implications for Immunoglobulin Therapy
  • Enhancing Hospital Discharge Prediction with Optimized Large Language Models: A Retrospective Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top